Background/Objectives: Traditionally consumed fermented foods and lactic acid bacteria (LAB)-based products have primarily been investigated for their nutritional and health-promoting benefits as dietary supplements. More recently, research has advanced toward exploring their therapeutic potential in pharmaceutical development. However, reliance on conventional LAB strains despite their established safety and efficacy has led to saturation at the strain level, underscoring the need for next-generation probiotics (NGPs) with novel therapeutic potential. In this context, we identified Flavonifractor plautii from human feces as a candidate NGP and investigated its effects on the human gut microbiota. Methods: Whole-genome sequencing revealed distinct genetic features that supported its uniqueness, and the strain was designated PMC93. A human gut microbial ecosystem simulator was used to administer F. plautii daily for one week, after which microbial community changes were evaluated using 16S rRNA gene-based metagenomic sequencing. Results: The administration did not induce significant changes in alpha or beta diversity, suggesting that F. plautii does not disrupt overall bacterial community structure, thereby supporting its microbial community safety. Taxonomic analysis demonstrated a significant increase in the Firmicutes-to-Proteobacteria ratio (NGP F/P index). The improvement surpassed that of conventional LAB treatments and was consistently maintained under supplementation with commonly encountered pharmaceutical compounds and nutrients. The shift was associated with an increase in short-chain fatty acid (SCFA)-producing beneficial taxa and a decrease in pro-inflammatory and potentially pathogenic groups. Functional outcomes, including elevated SCFA levels and downregulation of inflammation-related gene expression, further corroborated these compositional changes. The strain also demonstrated safety in in vivo models. Conclusions: Collectively, these findings suggest that strain PMC93 is a promising NGP candidate with substantial therapeutic potential for microbiota-associated health and disease modulation, particularly due to its ability to enhance the NGP F/P index.

The management of swine wastewater (SW) presents significant environmental challenges, requiring solutions that combine effective treatment with resource recovery. This study highlights the dual role of microalgae in wastewater remediation and bioenergy production. H. rubescens KNUA214 was cultivated in media containing varying concentrations of diluted swine wastewater (DSW; 0%, 25%, 50%, and 100%). Cultivating with Blue Green-11 (BG-11) medium + 50% DSW maximized biomass growth, the chlorophyll content, and carotenoid production. Nutrient removal efficiency in 100% DSW over 8 days demonstrated reductions of 59.3% in total nitrogen, 67.7% in ammonia nitrogen, and 40.7% in total phosphorus, confirming the species’ capacity for effective wastewater treatment. The carotenoid analysis using HPLC revealed that astaxanthin, lutein, canthaxanthin, and beta-carotene exhibited the highest levels in BG-11 + 50% DSW. Furthermore, the biomass analyses confirmed its potential for bioenergy applications, with high calorific values and significant polyunsaturated fatty acid concentrations, enhancing its utility for bioenergy and biolubricant production. These findings position H. rubescens KNUA214 as an effective resource for integrating SW management with the sustainable production of high-value biochemicals, offering environmental and economic benefits.